Thousands to potentially benefit from Roche treatment for sight loss
Faricimab is administered as an eye injection with an interval of up to 16 weeks
Read More
Tag: faricimab
Roche’s vision loss therapy faricimab extends time between treatments by up to four months
Results from four Phase III studies demonstrated non-inferior vision gains with extended dosing schedule
Read More
Roche’s faricimab hits the mark in diabetic macular edema study
Treatment demonstrated non-inferior visual acuity gains compared to Regeneron’s Eylea
Read More
Roche and Genentech take global macular degeneration step
Roche and Genentech have initiated two large global Phase III clinical trials testing the potential of faricimab in wet age-related macular degeneration.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
